Popular on eTradeWire
- - 200
- June 14, 2025 The Color Bar Joins "Outrun Hunger" - 191
- "Privacy" & more on PriceofBusiness.com: Latest Guest Posts & Articles for June 13th 202 - 163
- Eric F Gilbert Empowers Entrepreneurs Through Real-World Experience, No-Fluff Advice, - Proven Resu - 150
- Introducing GANCloud — The Future of Memory Starts Here - 142
- Finding My Plate - A Moving, Honest and Uplifting Children's Book by La'Nardo Myrick II - 141
- The Matrix Opal by Stella Atrium - A Dystopian Science Fiction Novel - 138
- Nature-Based Printables Help Rhode Island Families Turn Beach Days into Learning Adventures - 134
- NYC Leadership Strategist Stacie Selise Launches Groundbreaking 4S Framework Series to Redefine Executive Excellence - 125
- "Don't You Dare Give Up On God" (2nd Edition) Offers Unshakable Hope for Christians Struggling with Silence, Suffering, and Spiritual Burnout - 125
Similar on eTradeWire
- West Dentistry Welcomes New Oral Surgeon to Enhance Patient Care
- AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)
- Control Solutions Inc. awarded Biomedical Refrigeration & Freezer agreement with Premier, Inc
- $328 Million Global Stroke Rehab Market Opportunity Awaits AI Telehealth Leader Following Selection for NIH Funded Phase 3 Clinical Study: VSee Health
- $750 Million Ketamine Drug Market Withing Reach via New Commissioner's National Priority Vouchers with Anticipated Approval by Year-End for NRx
- Vision Share to Distribute KeraNatural® & halo® in Select Global Markets
- ArkBio's New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA
- Introducing GANCloud — The Future of Memory Starts Here
- ReproTech LLC Invests in Matcher Technologies Ltd
- $750 Million Market Projected to Reach $3.3 Billion Globally in 2034 for New Drug Application Filed on Preservative-Free IV Ketamine: NRx Pharma, Inc
Ace Therapeutics Launches Validated Disease Model Aiming to Elevate Gastroenterology Research to New
eTradeWire News/10805349
NEW YORK - eTradeWire -- Ace Therapeutics, a preclinical contract research organization dedicated to expediting research in gastroenterology and hepatology, recently unveiled well-validated disease models tailored for gastroenterology lab research. These models, developed through cutting-edge technologies like organoids, microfluidics, and CRISPR, aim to address critical gaps in understanding complex gastrointestinal (GI) disorders such as inflammatory bowel disease (IBD), gastroesophageal reflux disease (GERD), and hepatitis.
Disease models used for gastroenterology research are essential tools for understanding the pathophysiology of GI disorders, testing potential therapies, and driving forward clinical applications. Common models include in vitro models (cell culture models, organoids) and animal models (rat, mouse, non-human primates, etc.). In vitro models are used for studying cellular and molecular mechanisms of GI diseases like IBD, colorectal cancer, and infectious enteropathies. Animal models can provide insights into disease mechanisms and preclinical drug testing.
More on eTradeWire News
As a leading gastroenterology CRO (https://www.acetherapeutics.com/gi-and-hepatology/), Ace Therapeutics provides tailored preclinical gastrointestinal disease models using CRISPR genome editing, microbiome engineering, and rodent surgery for fast-track disease discovery and drug discovery. To be more specific, Ace Therapeutics' disease models mimic human GI pathophysiology with unprecedented accuracy, incorporating organoids and multi-omics data integration. This enables researchers to study disease progression and therapeutic responses in a controlled, scalable environment.
In addition, Ace Therapeutics' disease models are suitable for comprehensive coverage of GI disorders. From ulcerative colitis and Crohn's disease to non-alcoholic steatohepatitis (NASH) and gastric cancer, Ace Therapeutics offers an extensive portfolio. Each model incorporates key pathological features, such as immune dysregulation, microbiome interactions, and tissue fibrosis, enabling multi-target drug testing.
More on eTradeWire News
Leveraging advanced gene-editing, organoid cultures, and AI-driven data analytics, the models from Ace Therapeutics allow for personalized research approaches. Whether investigating novel biologics, small molecules, or microbiome-based therapies, researchers can tailor studies to specific mechanisms of interest. Furthermore, by minimizing variability and enhancing reliability, Ace Therapeutics can help shorten preclinical timelines and reduce R&D costs. Pharmaceutical companies and academic labs alike can expedite breakthroughs while optimizing resource allocation.
With a proven track record in gastroenterology research, Ace Therapeutics is the preferred gastroenterology CRO for biopharma innovators. Whether researchers are developing anti-fibrotic therapies, metabolic modulators, or oncology drugs, Ace Therapeutics' gastrointestinal and liver disease models deliver the robust preclinical data they need.
Disease models used for gastroenterology research are essential tools for understanding the pathophysiology of GI disorders, testing potential therapies, and driving forward clinical applications. Common models include in vitro models (cell culture models, organoids) and animal models (rat, mouse, non-human primates, etc.). In vitro models are used for studying cellular and molecular mechanisms of GI diseases like IBD, colorectal cancer, and infectious enteropathies. Animal models can provide insights into disease mechanisms and preclinical drug testing.
More on eTradeWire News
- "Interview Resurfaces as Count Jonathan of Aquitaine Gains International Attention"
- This Week Best-Selling Author Tom Wall Joins Tom Hegna on "Financial Freedom with Tom Hegna"
- Jamaican Health Policy Strategist Kavelle Christie Named to Caribbean-American Power 100 and Honored at POSH ICON Woman Awards
- The Taco Spot Expands to Florida with its 21st Location!
- Coming Up on "Financial Freedom with Tom Hegna" Leading Financial Speaker and Best-Selling Author Tom Wall
As a leading gastroenterology CRO (https://www.acetherapeutics.com/gi-and-hepatology/), Ace Therapeutics provides tailored preclinical gastrointestinal disease models using CRISPR genome editing, microbiome engineering, and rodent surgery for fast-track disease discovery and drug discovery. To be more specific, Ace Therapeutics' disease models mimic human GI pathophysiology with unprecedented accuracy, incorporating organoids and multi-omics data integration. This enables researchers to study disease progression and therapeutic responses in a controlled, scalable environment.
In addition, Ace Therapeutics' disease models are suitable for comprehensive coverage of GI disorders. From ulcerative colitis and Crohn's disease to non-alcoholic steatohepatitis (NASH) and gastric cancer, Ace Therapeutics offers an extensive portfolio. Each model incorporates key pathological features, such as immune dysregulation, microbiome interactions, and tissue fibrosis, enabling multi-target drug testing.
More on eTradeWire News
- GODSMACKED and HUMAN CLAY Bring the Ultimate Rock Tribute Experience to Boca Black Box on Sept 3
- Solid Factor Consulting Announces Free Strategic Business Training for Hispanic Entrepreneurs
- Stash Proof Launches Free Shipping on All Orders Nationwide
- John Duffy Hosts Sister Irene Neill, Founder and President, and Kelly Mallon Young
- Transformance Advisors Proudly Announces 128 Newly Certified Lean Practitioners
Leveraging advanced gene-editing, organoid cultures, and AI-driven data analytics, the models from Ace Therapeutics allow for personalized research approaches. Whether investigating novel biologics, small molecules, or microbiome-based therapies, researchers can tailor studies to specific mechanisms of interest. Furthermore, by minimizing variability and enhancing reliability, Ace Therapeutics can help shorten preclinical timelines and reduce R&D costs. Pharmaceutical companies and academic labs alike can expedite breakthroughs while optimizing resource allocation.
With a proven track record in gastroenterology research, Ace Therapeutics is the preferred gastroenterology CRO for biopharma innovators. Whether researchers are developing anti-fibrotic therapies, metabolic modulators, or oncology drugs, Ace Therapeutics' gastrointestinal and liver disease models deliver the robust preclinical data they need.
Source: Ace Therapeutics
Filed Under: Biotech
0 Comments
Latest on eTradeWire News
- Wordeee Publishes Am I a Weed? by Margie Stiles
- Summer Is the Best Time for a Roof Replacement, Says Oklahoma Roofing Expert
- New Quality Assurance and Training Manager Appointed at MITY, Inc
- Inframark Expands Automation & Intelligence Capabilities, Acquires Systems East, Inc.
- Wings of Hope: Butterfly Release and Remembrance Event
- Bobbi Rae Unveils Soul-Stirring New Single "Red Flags" -A Vulnerable Anthem for the Heartbroken
- Shark Tank Winner Tracey Noonan Launches Online Entrepreneurship Masterclass
- NASA Collaborative Agreement for Supply of Thin-Film Solar Tech for Orbital Application to Advance Development of Thin-Film PV Power Beaming: $ASTI
- HR Knowledge Source Named Finalist for Gwinnett Chamber's 2025 Moxie Awards
- Pat Munger Construction Company, Inc. Named #1 Family-Owned Business by Hartford Business Journal
- Georgia's Gwinnett County to Host Household Hazardous Waste Collection Day July 26
- Without a Program Like This, I Wouldn't Be Alive Today!
- Summer heat can turn a small crack into a broken windshield
- MYdys Wins Tech & Learning "Best of Show" at ISTELive 25 for Primary Education
- West Midlands conveyor company shortlisted for prestigious business award
- Sci-Fi Novel from Pittsburgh Author Explores Love, Power, & Humanity in an Age of Artificial People
- Build your game collection with pre-owned 8 liner game boards
- David Weekley Homes Teamed Up with HomeAid Georgia to Aid Atlanta Nonprofit
- Caldwell University Bowler Lauren Marks Named CSC First Team Academic All-American
- Shoot 'Em Up Classic Undeadline Coming to America & Europe for the First Time in New Collector's Set